^
Association details:
Biomarker:CD20 overexpression
Cancer:Peripheral T-cell Lymphoma
Regimen:CVAD (cyclophosphamide + dexamethasone injection + doxorubicin hydrochloride + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report

Excerpt:
A 65-year-old man was diagnosed with T-cell lymphoma with abundant CD20 expression. He was refractory to cyclophosphamide + epirubicin + vincristine + prednisone + etoposide (CHOPE), ifosfamide + cisplatin + etoposide + dexamethasone (DICE), and hyper-cyclophosphamide + vincristine + epirubicin + dexamethasone (CVAD) chemotherapy.
DOI:
10.1097/MD.0000000000010199.